Global pharmaceutical company Allergan has announced it will purchase clinical-stage biotechnology company Vitae Pharmaceuticals.
Medical spa group EF MEDISPA is launching its first franchise outside of London in Bristol
EF Medispa has introduced Swiss cellular skincare brand Cellcosmet to its London aesthetic clinics.
Global pharmaceutical company Actavis has confirmed that it will acquire Allergan for $66 billion, or $219 per share. The agreement sees Actavis purchase the Botox-maker for a combination of $129.22 in cash and 0.3683 Actavis shares, for each share of Allergan common stock.
Global healthcare company Galderma has announced that it has initiated a Phase II clinical trial of a liquid form of botulinum toxin in the US. The multicentre, dose-range study will evaluate the safety and effectiveness of Galderma’s internally developed liquid form of botulinum toxin for the treatment of glabellar lines.
Sanofi has announced the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc for $425 million (US).